Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 843

1.

How I treat cold agglutinin hemolytic anemia.

Gertz MA.

Clin Adv Hematol Oncol. 2019 Jun;17(6):338-343. No abstract available.

PMID:
31437137
2.

Advances in the treatment of hereditary transthyretin amyloidosis: A review.

Gertz MA, Mauermann ML, Grogan M, Coelho T.

Brain Behav. 2019 Aug 1:e01371. doi: 10.1002/brb3.1371. [Epub ahead of print] Review.

3.

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Amyloid. 2019;26(sup1):101-102. doi: 10.1080/13506129.2019.1582486. No abstract available.

PMID:
31343331
4.

Therapy of Transthyretin Cardiomyopathy.

Gertz MA.

J Am Coll Cardiol. 2019 Jul 23;74(3):296-298. doi: 10.1016/j.jacc.2019.05.031. No abstract available.

PMID:
31319911
5.

The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors.

Alkharabsheh O, Sidiqi MH, Aljama MA, Gertz MA, Frankel AE.

Acta Haematol. 2019 Jul 16:1-6. doi: 10.1159/000500976. [Epub ahead of print] Review.

6.

Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.

Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Br J Haematol. 2019 Jul 12. doi: 10.1111/bjh.16096. [Epub ahead of print]

PMID:
31298751
7.

Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis.

Al Saleh AS, Sidiqi MH, Sidana S, Muchtar E, Dispenzieri A, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Wolf RC, Kapoor P, Buadi FK, Kumar SK, Gertz MA.

Am J Hematol. 2019 Jul 4. doi: 10.1002/ajh.25572. [Epub ahead of print]

PMID:
31273808
8.

Improvement in Gastrointestinal Symptoms From Light Chain Amyloidosis After Adalimumab Therapy.

Al Saleh AS, Sidiqi MH, Gertz MA.

Mayo Clin Proc. 2019 Jul;94(7):1380-1381. doi: 10.1016/j.mayocp.2019.04.023. No abstract available.

PMID:
31272581
9.

Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.

Gertz MA, Scheinberg M, Waddington-Cruz M, Heitner SB, Karam C, Drachman B, Khella S, Whelan C, Obici L.

Expert Rev Clin Pharmacol. 2019 Aug;12(8):701-711. doi: 10.1080/17512433.2019.1635008. Epub 2019 Jul 3. Review.

PMID:
31268366
10.

Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.

Sidana S, Sidiqi MH, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Leung N, Warsame R, Kourelis TV, Wolf RC, Hogan WJ, Kumar SK, Gertz MA.

Am J Hematol. 2019 Jun 28. doi: 10.1002/ajh.25566. [Epub ahead of print]

PMID:
31254301
11.

Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis.

Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, Paludo J.

Cancer. 2019 Jun 28. doi: 10.1002/cncr.32357. [Epub ahead of print]

PMID:
31251390
12.

Impact of acquired del(17p) in multiple myeloma.

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Adv. 2019 Jul 9;3(13):1930-1938. doi: 10.1182/bloodadvances.2018028530.

13.

Correction: Waldenström macroglobulinemia treatment algorithm 2018.

Gertz MA.

Blood Cancer J. 2019 Jun 25;9(7):53. doi: 10.1038/s41408-019-0212-x.

14.

The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma.

Miller KC, Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Muchtar E, Hogan WJ, Kumar SK.

Bone Marrow Transplant. 2019 Jun 12. doi: 10.1038/s41409-019-0590-5. [Epub ahead of print]

PMID:
31190005
15.

Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis.

Venkatesh SK, Hoodeshenas S, Venkatesh SH, Dispenzieri A, Gertz MA, Torbenson MS, Ehman RL.

J Clin Med. 2019 May 23;8(5). pii: E739. doi: 10.3390/jcm8050739.

16.

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Leuk Lymphoma. 2019 May 16:1-8. doi: 10.1080/10428194.2019.1613536. [Epub ahead of print]

PMID:
31096812
17.

Burden of hereditary transthyretin amyloidosis on quality of life.

Yarlas A, Gertz MA, Dasgupta NR, Obici L, Pollock M, Ackermann EJ, Lovley A, Kessler AS, Patel PA, White MK, Guthrie SD.

Muscle Nerve. 2019 Aug;60(2):169-175. doi: 10.1002/mus.26515. Epub 2019 Jun 13.

PMID:
31093980
18.

Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.

Al Saleh AS, Sidiqi MH, Muchtar E, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1520-1525. doi: 10.1016/j.bbmt.2019.04.024. Epub 2019 May 2.

PMID:
31054986
19.

Multiple myeloma and kidney transplantation: the beginning of a new era.

Van den Bosch I, Sprangers B, Gertz M.

Clin Kidney J. 2019 Mar 1;12(2):213-215. doi: 10.1093/ckj/sfz003. eCollection 2019 Apr.

20.

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.

Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2019 Apr 23;3(8):1226-1229. doi: 10.1182/bloodadvances.2019032458.

21.

Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function.

Sidiqi MH, Nadiminti K, Al Saleh AS, Meleveedu K, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Bone Marrow Transplant. 2019 Apr 8. doi: 10.1038/s41409-019-0524-2. [Epub ahead of print]

PMID:
30962503
22.

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.

Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2019 Jul;94(7):751-756. doi: 10.1002/ajh.25481. Epub 2019 Apr 30.

PMID:
30945330
23.

Natural history of multiple myeloma with de novo del(17p).

Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2019 Mar 7;9(3):32. doi: 10.1038/s41408-019-0191-y.

24.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2019 Apr;33(4):1058-1059. doi: 10.1038/s41375-019-0410-3.

PMID:
30842604
25.

Two types of amyloidosis presenting in a single patient: a case series.

Sidiqi MH, McPhail ED, Theis JD, Dasari S, Vrana JA, Drosou ME, Leung N, Hayman S, Rajkumar SV, Warsame R, Ansell SM, Gertz MA, Grogan M, Dispenzieri A.

Blood Cancer J. 2019 Mar 5;9(3):30. doi: 10.1038/s41408-019-0193-9.

26.

Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.

Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, Kourelis TV, Buadi FK, Kapoor P, Gonsalves W, Warsame R, Lacy MQ, Kyle RA, Rajkumar SV, Kumar SK, Leung N.

Br J Haematol. 2019 May;185(4):701-707. doi: 10.1111/bjh.15832. Epub 2019 Mar 5.

PMID:
30836444
27.

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma.

Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Kumar SK.

Blood Adv. 2019 Mar 12;3(5):744-750. doi: 10.1182/bloodadvances.2018022806.

28.

The colorful landscape of multiple myeloma.

Muchtar E, Gertz MA.

Leuk Lymphoma. 2019 Feb 27:1-2. doi: 10.1080/10428194.2019.1585842. [Epub ahead of print] No abstract available.

PMID:
30810426
29.

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.

Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK.

Leukemia. 2019 May;33(5):1273-1277. doi: 10.1038/s41375-019-0419-7. Epub 2019 Feb 20.

PMID:
30787429
30.

Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis.

Sidiqi MH, Dasari S, McPhail ED, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kapoor P, Kourelis T, Leung N, Muchtar E, Grogan M, Lust JA, Kumar S, Kyle RA, Rajkumar VS, Gertz M, Dispenzieri A.

Am J Hematol. 2019 May;94(5):E141-E143. doi: 10.1002/ajh.25440. Epub 2019 Feb 27. No abstract available.

PMID:
30773682
31.

A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing.

Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Kumar SK, Dispenzieri A.

Mayo Clin Proc. 2019 Mar;94(3):472-483. doi: 10.1016/j.mayocp.2018.08.006. Epub 2019 Feb 13. Erratum in: Mayo Clin Proc. 2019 Jun;94(6):1121.

PMID:
30770096
32.

Substratification of patients with newly diagnosed standard-risk multiple myeloma.

Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK.

Br J Haematol. 2019 Apr;185(2):254-260. doi: 10.1111/bjh.15800. Epub 2019 Feb 15.

PMID:
30768679
33.

Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.

Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A.

Leukemia. 2019 May;33(5):1268-1272. doi: 10.1038/s41375-019-0400-5. Epub 2019 Feb 8.

PMID:
30737485
34.

Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis.

Sidana S, Tandon N, Brady PA, Grogan M, Gertz MA, Dispenzieri A, Lin G, Dingli D, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Muchtar E, Warsame R, Kumar SK, Kourelis TV.

Mayo Clin Proc. 2019 Mar;94(3):455-464. doi: 10.1016/j.mayocp.2018.08.039. Epub 2019 Feb 2.

PMID:
30718070
35.

Risk adapted post-transplant maintenance in multiple myeloma.

Vaxman I, Gertz M.

Expert Rev Hematol. 2019 Feb;12(2):107-118. doi: 10.1080/17474086.2019.1576521.

PMID:
30696304
36.

Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Greipp PT, Baughn LB, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 May;94(5):E117-E120. doi: 10.1002/ajh.25420. Epub 2019 Feb 6. No abstract available.

PMID:
30680770
37.

Comparative analysis of staging systems in AL amyloidosis.

Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A.

Leukemia. 2019 Mar;33(3):811-814. doi: 10.1038/s41375-018-0370-z. Epub 2019 Jan 23. No abstract available.

PMID:
30675009
38.

Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.

Vaxman I, Gertz M.

Acta Haematol. 2019;141(2):93-106. doi: 10.1159/000495455. Epub 2019 Jan 16. Review.

39.

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.

Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK.

Am J Hematol. 2019 Apr;94(4):424-430. doi: 10.1002/ajh.25391. Epub 2019 Jan 8.

PMID:
30592078
40.

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay.

Muchtar E, Kumar SK, Gertz MA, Grogan M, AbouEzzeddine OF, Jaffe AS, Dispenzieri A.

Blood. 2019 Feb 14;133(7):763-766. doi: 10.1182/blood-2018-10-875252. Epub 2018 Dec 13. No abstract available.

PMID:
30545829
41.

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome.

Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV.

Blood Cancer J. 2018 Dec 11;8(12):125. doi: 10.1038/s41408-018-0163-7.

42.

Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.

Sidiqi MH, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e108-e111. doi: 10.1016/j.bbmt.2018.12.003. Epub 2018 Dec 7.

PMID:
30529461
43.

Current role of high dose chemotherapy in the management of multiple myeloma.

Gertz MA.

Leuk Lymphoma. 2019 Jun;60(6):1349-1351. doi: 10.1080/10428194.2018.1533131. Epub 2018 Dec 11. No abstract available.

PMID:
30526195
44.

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma.

Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2019 Mar;94(3):306-311. doi: 10.1002/ajh.25365. Epub 2018 Dec 13.

PMID:
30516847
45.

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.

Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK.

Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.

46.

Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.

Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV.

Blood Cancer J. 2018 Nov 15;8(12):116. doi: 10.1038/s41408-018-0140-1.

47.

Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.

Kumar SK, Gertz MA, Dispenzieri A.

J Clin Oncol. 2019 Jan 10;37(2):171-173. doi: 10.1200/JCO.18.01398. Epub 2018 Nov 15. No abstract available.

PMID:
30433848
48.

Venetoclax for the treatment of multiple myeloma.

Vaxman I, Sidiqi MH, Gertz M.

Expert Rev Hematol. 2018 Dec;11(12):915-920. doi: 10.1080/17474086.2018.1548931. Epub 2018 Dec 6.

PMID:
30428277
49.

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.

Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA.

Blood Cancer J. 2018 Nov 8;8(11):106. doi: 10.1038/s41408-018-0147-7.

50.

Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Wolf RC, Kumar SK, Gertz MA.

Bone Marrow Transplant. 2019 Jul;54(7):1077-1081. doi: 10.1038/s41409-018-0388-x. Epub 2018 Nov 2.

PMID:
30390060

Supplemental Content

Support Center